MOUNTAIN VIEW, Calif.,
Jan. 17, 2012 /PRNewswire/
-- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced
the appointment of W. James O'Shea to its Board of Directors. Mr.
O'Shea brings to the Board 35 years of healthcare industry
experience in product commercialization and operations.
"We are privileged to welcome Jim to our Board of Directors at
this exciting time in the Company's development as we focus our
efforts on building a commercial infrastructure to support the
launch and commercialization of LEVADEX, if approved," said
Timothy S. Nelson, president and
chief executive officer of MAP Pharmaceuticals. "The depth of Jim's
experience in commercializing new pharmaceutical products in
specialist markets will provide great value and we look forward to
benefitting from his expertise as we advance LEVADEX."
Mr. O'Shea has extensive experience in the healthcare industry,
including eight years at Sepracor where he held various roles in
operations and commercialization most recently as Vice Chairman and
previously as President and Chief Operating Officer. Prior to
Sepracor, Mr. O'Shea held several management positions of
increasing responsibility in international sales and marketing,
including Senior Vice President of Sales and Marketing and Medical
Affairs for Zeneca Pharmaceuticals, a business unit of Astra Zeneca
Plc,. Mr. O'Shea has led the commercial launch of over 10 new
products in several therapeutic areas, including migraine and
pain.
Mr. O'Shea is a graduate of Liverpool Lord Byron University, where he received an honors
degree in applied physics from the Institute of Physics.
About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused on
developing and commercializing new therapies to address undermet
patient needs in neurology. The Company is developing LEVADEX®, an
orally inhaled investigational drug for the acute treatment of
migraine. The New Drug Application for LEVADEX is currently under
review by the U.S. Food and Drug Administration. MAP
Pharmaceuticals has entered into a collaboration agreement with
Allergan, Inc. to co-promote LEVADEX to neurologists and pain
specialists in the U.S. and Canada. The Company also applies its
proprietary drug particle and inhalation technologies to generate
new pipeline opportunities by enhancing the therapeutic benefits of
proven drugs, while minimizing risk by capitalizing on their known
safety, efficacy and commercialization history. Additional
information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
Forward-Looking Statements
In addition to statements of historical facts or statements of
current conditions, this press release contains forward-looking
statements, including with respect to MAP Pharmaceuticals' LEVADEX
product candidate. Actual results may differ materially from
current expectations based on risks and uncertainties affecting the
Company's business, including, without limitation, risks and
uncertainties relating to the regulatory process to have the
Company's LEVADEX product candidate approved for commercial use and
the commercialization of LEVADEX, if approved. The reader is
cautioned not to unduly rely on the forward-looking statements
contained in this press release. MAP Pharmaceuticals expressly
disclaims any intent or obligation to update these forward-looking
statements, except as required by law. Additional information on
potential factors that could affect MAP Pharmaceuticals' results
and other risks and uncertainties are detailed in its Quarterly
Report on Form 10-Q for the quarter ended October 31, 2011, available at
http://edgar.sec.gov.
Contact:
|
|
Lisa
Borland
|
|
650-386-3122
|
|
lborland@mappharma.com
|
|
|
|
SOURCE MAP Pharmaceuticals, Inc.